RESULTS:
Of the 1393 blood samples, ZIKV RNA was detected in 37 (n 5 37/1393; 2.7%). The median infection viral load detected was 7714 copies/mL (ranging from 135-124,220 copies/mL). The majority of the positive samples (70.3%) exhibited a viral load of approximately 10 3 copies/mL. Six samples that were positive for ZIKV RNA were also positive for anti-ZIKV IgM and IgG (n 5 6/37; 13.5%).
CONCLUSION: This is the first study evaluating the prevalence of ZIKV RNA among Brazilian blood donors, which was relatively high and might lead to TT-ZIKV infection. It is unclear whether the simultaneous presence of anti-ZIKV IgM and IgG in RNA-positive donations or the viral load influences transfusion transmission of the infection. This study also adds to the global understanding of ZIKV prevalence in blood donors during outbreaks and the transfusion impact of the infection.
Z ika virus (ZIKV) is a member of the Flaviviridae family (genus Flavivirus).
The virus, which is primarily transmitted by Aedes mosquitos, causes a mild febrile disease often associated with exanthema and arthralgia. ZIKV has also been related to severe neurologic complications including microcephaly in neonates (via transplacental transmission) and Guillain-Barr e syndrome in adults. 1 In the majority of cases, however, the infection takes an asymptomatic or oligosymptomatic course, and a significant proportion of infected individuals do not seek medical attention. 4 Moreover, transfusion-transmitted ZIKV (TT-ZIKV) by platelet components has been documented in Brazil. 5, 6 Therefore, it is important to investigate the presence of ZIKV RNA in asymptomatic blood donors during outbreaks to prevent TT-ZIKV. The aim of this study was to evaluate the prevalence of ZIKV asymptomatic infection among Brazilian blood donors in a region with a large outbreak located in the southeastern part of the country (northeast of São Paulo State). Despite the extensive dissemination of ZIKV in Brazil, the occurrence of ZIKV RNA among blood donors is unknown.
MATERIALS AND METHODS
The Municipal Epidemiological Surveillance Agency estimated approximately 5379 suspected ZIKV cases and 38,881 confirmed Dengue virus (DENV) cases for the period from October 2015 to May 2016 (http://www.saude. ribeiraopreto.sp.gov.br/ssaude/pdf/dengue_balanco.pdf; Fig. 1) . However, the real number of ZIKV-infected individuals is probably underestimated because the infection was confirmed based only on the presence of clinical symptoms; therefore, the actual number might be much higher.
From October 2015 to May 2016, plasma samples were collected from 1393 of 8936 voluntary blood donors who fulfilled all of the criteria for blood donation (sample number calculated based on approximately 8000 donations; relative error, 20%; confidence coefficient, 95%; supposed ZIKV RNA prevalence, 5%). This study was blinded to comply with Brazilian laws for blood donation that require the absolute privacy of donor personal data (Decree 158, February 4, 2016) . At the time of blood collection, blood donors were consented for their samples to be tested for ZIKV RNA. The obtained samples were unlinked with no personal identifiers available to the researchers. The blinded study design was used because the ZIKV RNA detection test was performed for research purposes with an in-house method that was not approved for routine diagnosis and testing was performed retrospectively due to lack of testing automation. The study was approved by the Ethical Committee of the General Hospital of Ribeirão Preto, Faculty of Medicine of Ribeirão Preto (Process 2056/2015).
Four milliliters of peripheral blood was collected in sterile EDTA tubes (Vacuette, Greiner Bio-One). Plasma was separated by low-speed centrifugation (1426 3 g, 10 min).
All of the samples were tested individually. Viral RNA was manually extracted from 140 mL of plasma using a viral RNA mini kit (QIAamp, Qiagen) following the manufacturer's instructions. Reverse transcription was performed using the high-capacity cDNA reverse transcription kit (ThermoFisher Scientific) and a specific ZIKV reverse primer in a final volume of 20 mL. A standard reverse transcription protocol was used that consisted of one stage at 378C for 2 hours and a denaturation step at 858C for 5 minutes. A previously described primer pair 7 targeting a 76-bp fragment of the ZIKV Asian lineage was used to quantitatively diagnose viral infection. The primer pair is specific for ZIKV RNA detection, as it did not cross-react with genomes from other Brazilian arboviruses (Ilh eus virus; Bussuquara virus; West Nile virus; Iguape virus; Cacipacore virus; DENV 1-4; yellow fever; ZIKV; Oropouche virus; Mucambo virus; and East, West, and Venezuelan equine encephalitis viruses; 100% analytic specificity). The diagnostic specificity of the test was assessed with blinded samples, including 84 ZIKV RNA-negative samples that were randomly mixed with three DENV 1-, 2-, and 4-positive samples and nine ZIKVpositive samples. Positive amplification was observed for the eight ZIKV RNA-positive samples demonstrating 100% diagnostic specificity. Viral RNA was quantified using a standard curve obtained after serial decimal dilutions of the respective fragment cloned into cloning vector (pCR V R 2.1-TOPO, ThermoFisher Scientific). The positive control was an Asian ZIKV strain derived from a positive plasma unit of an infected blood donor that was then grown in VERO E6 cells. The dynamic range of the assay was 10 6 to 1 copies/ reaction, and the 50% and 95% limits of detection were 1 and 13.9 copies/reaction, respectively, as calculated by the Probit linear regression algorithm (probability 95%, SPSS Version 17 statistical software, IBM Corp.). The obtained sensitivity of the test was 99.3 copies/mL. The standard curve demonstrated the appropriate variables for viral quantitation (efficiency, 106%; R 2 5 0.95). Amplification was performed using a standard amplification protocol (508C for 5 min, 958C for 10 min and 40 cycles of 958C for 30 sec, and 608C for 1 min) in a real-time system (ABI 7500, ThermoFisher Scientific). A result was considered ZIKV-positive if the amplification exhibited a Ct of at least 38. The ZIKV RNA-positive samples were also tested for DENV and chikungunya virus (CHIKV) with primers and probes found in the literature 8, 9 to exclude the possibility that both arboviruses were circulating at the same time in our region. Samples positive for ZIKV RNA were also tested for anti-ZIKV IgM (Diagnostic Bioprobes) and IgG (Euroimmun), each following the manufacturers' instructions.
RESULTS
Among the 1393 blood samples tested between October 2015 and May 2016, ZIKV RNA was detected in 37 (n 5 37/ 1393; 2.7%). The initially positive ZIKV samples were extracted again by a different operator and confirmed using real-time polymerase chain reaction (TaqMan, ThermoFisher Scientific). All retested samples were positive for ZIKV RNA. Viral loads ranged from 135 to 124,220 copies/mL (median, 7714 copies/mL). A significant proportion of the positive samples exhibited a viral load of approximately 10 3 copies/mL (n 5 26/37, 70.3%); the other samples had viral loads of approximately 10 2 copies/mL (n 5 6/37, 16.2%), approximately 10 4 (n 5 4/37, 10.8%), and approximately 10 5 (n 5 1/37, 2.7%).
The peak for positive ZIKV RNA samples was in April 2016 ( Fig. 1, tropical summer accompanied by heavy rainfalls), which coincided with higher mosquito proliferation and an increased number of notified ZIKV cases in our region. The finding that positive ZIKV RNA samples were also detected in 2015 (October-December), albeit at lower numbers than from January-May 2016, demonstrated that ZIKV has likely been circulating in the region at subepidemic levels or was misdiagnosed as DENV. This result also coincides with the number of suspected ZIKV cases notified between October and December 2015 by the Municipal Health Agency (Fig. 1) .
The ZIKV RNA-positive samples were also tested for anti-ZIKV IgM and IgG, and six of them were positive (n 5 6/37; 16.2%). The samples that were positive for anti-ZIKV IgM and anti-ZIKV IgG had viral loads between 10 3 and 10 4 copies/mL (lowest viral load 1034 copies/mL; highest 12,047 copies/mL; Table 1 
DISCUSSION
This study is the first to evaluate the prevalence of ZIKV RNA among blood donors in Brazil during a large outbreak in the northeast part of São Paulo State, Brazil. ZIKV RNA was detected in 37 of 1393 single blood donations (2.7%). Furthermore, six of the samples positive for RNA were also positive for anti-ZIKV IgM/IgG (n 5 6/37). These results suggest that a considerable proportion of blood donors in this region were infected with ZIKV. However, no TT-ZIKV cases were documented. Thus far, no clinical repercussions have been verified from TT-ZIKV cases. This situation parallels most transfusion-transmitted DENV episodes 10 because it is difficult to distinguish vectorial from transfusion transmission during outbreaks. However, due to the high rate of RNA-positive donors in our region, it is very likely that TT-ZIKV occurred. Limitations of our study include the fact that testing was performed blinded such that no investigation of recipients for possible TT-ZIKV or donor follow-up for seroconversion or the development of clinical symptoms could occur. Our study was relatively small and performed in a limited geographic location. We performed individualdonor screening for ZIKV RNA instead of minipool testing. In some cases, the detected viral load was low and combined with the sensitivity of the applied assay might lead to false-negative results. Along this line, a study evaluating ZIKV prevalence in the continental United States demonstrated that minipool screening for ZIKV RNA would have detected only 50% of positive blood donations despite the superior sensitivity of their assay compared with that of our assay.
11 A viral load of approximately 10 3 copies/mL was detected in the majority of ZIKV RNA-positive samples. It has been demonstrated that ZIKV RNA is present at a low viral load 12 and can persist for 14 and 54 days in serum. 13 Therefore, it is unknown if the detected viral load was the result of prolonged virus carriage or acute viral infection. Six of the samples positive for ZIKV RNA also contained ZIKV IgM and/or anti-ZIKV IgG. It is currently unknown if the presence of anti-ZIKV IgM and IgG concomitant with viral RNA reduces ZIKV transmission by blood transfusion. The serologic status of the recipient is also important, as it is possible that the presence of circulating antibodies can prevent the transfusion transmission of low viral load ZIKV, which has been described for other viral infections. 14 However, the infectious dose of ZIKV required to result in infection in a blood recipient is unknown. More studies evaluating innate immunity to ZIKV in both blood recipients and donors, the presence of immune modulators, viral genetic factors, and accurate viral load estimations in blood components are necessary to obtain a clearer overview of ZIKV transmission by blood. Another limitation of our study was that the serologic tests were performed only on ZIKV RNA-positive samples; therefore, we cannot evaluate overall ZIKV seropositivity in the studied group. In this regard, serologic surveys with a larger number of blood donors from endemic areas are necessary to evaluate the impact of ZIKV on transfusion safety.
The prevalence of asymptomatic ZIKV infection in Brazilian blood donors is unknown. Our results were identical to those obtained in French Polynesia (2.8%). 4 However, the obtained prevalence in our study was higher than that reported in Martinique (1.84%) 2 and the continental United States (0.006%).
11
It is unclear if laboratory testing for ZIKV in blood donors is currently needed to prevent TT-ZIKV (only three asymptomatic TT-ZIKV cases have been reported in Brazil). The higher risk of vectorial ZIKV transmission makes the application of such tests ineffective in blood banks. Additionally, the magnitude of ZIKV outbreaks is unpredictable, a high percentage of infected persons fail to develop symptoms, and a high percentage of the population develops immunity, which all influence the risk of TT-ZIKV and the need for an intervention. This situation is similar to DENV, an arbovirus that can be transmitted by blood transfusion and causes serious clinical consequences in some cases including hemorrhagic outcomes. Despite a large distribution and frequent outbreaks in Brazil, Brazilian blood banks and health authorities have never implemented specific measures to control transfusion-transmitted DENV. In our opinion, the best solution for controlling transfusion transmission of urban arboviruses is a multiplexed real-time method to detect ZIKV, DENV, or CHIKV in blood donors or approved pathogen reduction technologies. Such strategies, however, must be carefully balanced against other major health issues of national significance.
The management of the ZIKV outbreak in our region was a difficult issue because of its rapid emergence, the absence of ZIKV nucleic acid testing, and its initial erroneous attribution solely to DENV. Moreover, the public health system was not prepared to attend to all infected patients, much less to establish measures to prevent TT-ZIKV. Nevertheless, our study provides valuable information on the prevalence and viral load of asymptomatic ZIKV infections in Brazilian blood donors.
